Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China To Revise Law On Patent Abuse

This article was originally published in PharmAsia News

Executive Summary

A draft of China's revised patent law will be submitted to the Standing Committee of the National People's Congress for review on Aug. 25. A key point of the revision is the restriction of patent rights abuse. The draft explains that in situations where public health is threatened by epidemics or infectious diseases, the patent administrative department under State Council can decide on imposing a mandatory licensing system for drugs to guarantee adequate supply. Bolar Exception rules are also included (PharmAsia News, July 22, 2008). If passed, the new law will benefit local firms, which are increasingly facing pharmaceutical MNC charges on patent infringement. (Click here for more - Chinese Language)

You may also be interested in...

Insider Analysis From Jones Day: What Does the 3rd Amendment to China’s Patent Law Mean to Pharmaceutical Companies?

What Justice Ginsburg’s Death Means For Pharma

A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts